ABSORICA LD Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Absorica Ld, and when can generic versions of Absorica Ld launch?
Absorica Ld is a drug marketed by Sun Pharm and is included in one NDA. There are two patents protecting this drug.
This drug has seventeen patent family members in nine countries.
The generic ingredient in ABSORICA LD is isotretinoin. There are thirteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the isotretinoin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Absorica Ld
A generic version of ABSORICA LD was approved as isotretinoin by AMNEAL PHARMS NY on September 29th, 2017.
Summary for ABSORICA LD
| International Patents: | 17 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 73 |
| Clinical Trials: | 9 |
| Patent Applications: | 7,681 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ABSORICA LD |
| DailyMed Link: | ABSORICA LD at DailyMed |
Recent Clinical Trials for ABSORICA LD
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Children's Oncology Group | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
| Sun Pharmaceutical Industries Limited | Phase 4 |
Pharmacology for ABSORICA LD
| Drug Class | Retinoid |
Anatomical Therapeutic Chemical (ATC) Classes for ABSORICA LD
US Patents and Regulatory Information for ABSORICA LD
ABSORICA LD is protected by two US patents.
Patents protecting ABSORICA LD
Oral pharmaceutical composition of isotretinoin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Low dose oral pharmaceutical composition of isotretinoin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-001 | Nov 5, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-004 | Nov 5, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-002 | Nov 5, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-006 | Nov 5, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-004 | Nov 5, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-001 | Nov 5, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Sun Pharm | ABSORICA LD | isotretinoin | CAPSULE;ORAL | 211913-002 | Nov 5, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ABSORICA LD
See the table below for patents covering ABSORICA LD around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2015294993 | ⤷ Try a Trial | |
| Australia | 2015326489 | ⤷ Try a Trial | |
| Canada | 2963206 | ⤷ Try a Trial | |
| European Patent Office | 3200877 | ⤷ Try a Trial | |
| Mexico | 2017004312 | COMPOSICION FARMACEUTICA ORAL DE BAJA DOSIS DE ISOTRETINOINA. (LOW DOSE ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN.) | ⤷ Try a Trial |
| Japan | 2017521470 | イソトレチノインの経口医薬組成物 | ⤷ Try a Trial |
| Japan | 2017530149 | 低用量経口イソトレチノイン医薬組成物 | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
